RNAi for Therapeutic Market Report

Global and Region RNAi for Therapeutic Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 31, 2022
  • PAGES：201
  • REPORT CODE：GMM943734
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.

    The report details the trend, potential and market size of RNAi for Therapeutic market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of RNAi for Therapeuticmarket, defines the market attractiveness level of RNAi for Therapeutic market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of RNAi for Therapeutic industry, describes the types of RNAi for Therapeutic market, the applications of major players and the market size, and deeply analyzes the current situation of the global RNAi for Therapeutic market and the development prospects and opportunities of RNAi for Therapeutic industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global RNAi for Therapeutic market in Chapter 13.

    By Player:

    • Dicerna Pharmaceuticals

    • Arrowhead

    • Gradalis

    • miRagen Therapeutics

    • RXi Pharmaceuticals

    • Alnylam Pharmaceuticals

    • Quark Pharmaceuticals

    • Sirnaomics

    • Mirna Therapeutics

    By Type:

    • siRNA

    • miRNA

    • shRNA

    By End-User:

    • Cancer

    • Cardiovascular

    • HBV

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 RNAi for Therapeutic Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 RNAi for Therapeutic Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 RNAi for Therapeutic Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 RNAi for Therapeutic Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise RNAi for Therapeutic Market Analysis and Outlook to 2022

    • 7.1 Global RNAi for Therapeutic Consumption (2017-2022)

    • 7.2 United States RNAi for Therapeutic Consumption (2017-2022)

    • 7.3 Europe RNAi for Therapeutic Consumption (2017-2022)

    • 7.4 China RNAi for Therapeutic Consumption (2017-2022)

    • 7.5 Japan RNAi for Therapeutic Consumption (2017-2022)

    • 7.6 India RNAi for Therapeutic Consumption (2017-2022)

    • 7.7 South Korea RNAi for Therapeutic Consumption (2017-2022)

    8 Region and Country-wise RNAi for Therapeutic Market Analysis and Outlook to 2028

    • 8.1 Global RNAi for Therapeutic Consumption Forecast (2022-2028)

    • 8.2 United States RNAi for Therapeutic Consumption Forecast (2022-2028)

    • 8.3 Europe RNAi for Therapeutic Consumption Forecast (2022-2028)

    • 8.4 China RNAi for Therapeutic Consumption Forecast (2022-2028)

    • 8.5 Japan RNAi for Therapeutic Consumption Forecast (2022-2028)

    • 8.6 India RNAi for Therapeutic Consumption Forecast (2022-2028)

    • 8.7 South Korea RNAi for Therapeutic Consumption Forecast (2022-2028)

    9 Global RNAi for Therapeutic Market Outlook by Types and Applications to 2022

    • 9.1 Global RNAi for Therapeutic Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global siRNA Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global miRNA Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global shRNA Consumption and Growth Rate (2017-2022)

    • 9.2 Global RNAi for Therapeutic Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Cancer Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Cardiovascular Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global HBV Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Others Consumption and Growth Rate (2017-2022)

    10 Global RNAi for Therapeutic Market Outlook by Types and Applications to 2028

    • 10.1 Global RNAi for Therapeutic Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global siRNA Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global miRNA Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global shRNA Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global RNAi for Therapeutic Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Cancer Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Cardiovascular Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global HBV Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.4 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global RNAi for Therapeutic Import and Export Analysis (Top 5 Countries)

    • 11.1 Global RNAi for Therapeutic Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global RNAi for Therapeutic Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 RNAi for Therapeutic Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global RNAi for Therapeutic Market Competitive Analysis

    • 14.1 Dicerna Pharmaceuticals

      • 14.1.1 Dicerna Pharmaceuticals Company Details

      • 14.1.2 Dicerna Pharmaceuticals RNAi for Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Dicerna Pharmaceuticals RNAi for Therapeutic Product and Service

    • 14.2 Arrowhead

      • 14.2.1 Arrowhead Company Details

      • 14.2.2 Arrowhead RNAi for Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Arrowhead RNAi for Therapeutic Product and Service

    • 14.3 Gradalis

      • 14.3.1 Gradalis Company Details

      • 14.3.2 Gradalis RNAi for Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Gradalis RNAi for Therapeutic Product and Service

    • 14.4 miRagen Therapeutics

      • 14.4.1 miRagen Therapeutics Company Details

      • 14.4.2 miRagen Therapeutics RNAi for Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 miRagen Therapeutics RNAi for Therapeutic Product and Service

    • 14.5 RXi Pharmaceuticals

      • 14.5.1 RXi Pharmaceuticals Company Details

      • 14.5.2 RXi Pharmaceuticals RNAi for Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 RXi Pharmaceuticals RNAi for Therapeutic Product and Service

    • 14.6 Alnylam Pharmaceuticals

      • 14.6.1 Alnylam Pharmaceuticals Company Details

      • 14.6.2 Alnylam Pharmaceuticals RNAi for Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Alnylam Pharmaceuticals RNAi for Therapeutic Product and Service

    • 14.7 Quark Pharmaceuticals

      • 14.7.1 Quark Pharmaceuticals Company Details

      • 14.7.2 Quark Pharmaceuticals RNAi for Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Quark Pharmaceuticals RNAi for Therapeutic Product and Service

    • 14.8 Sirnaomics

      • 14.8.1 Sirnaomics Company Details

      • 14.8.2 Sirnaomics RNAi for Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Sirnaomics RNAi for Therapeutic Product and Service

    • 14.9 Mirna Therapeutics

      • 14.9.1 Mirna Therapeutics Company Details

      • 14.9.2 Mirna Therapeutics RNAi for Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Mirna Therapeutics RNAi for Therapeutic Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of RNAi for Therapeutic

    • Figure RNAi for Therapeutic Picture

    • Table Global RNAi for Therapeutic Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global RNAi for Therapeutic Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global RNAi for Therapeutic Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global RNAi for Therapeutic Consumption by Country (2017-2022)

    • Figure United States RNAi for Therapeutic Consumption and Growth Rate (2017-2022)

    • Table Europe RNAi for Therapeutic Consumption and Growth Rate (2017-2022)

    • Figure China RNAi for Therapeutic Consumption and Growth Rate (2017-2022)

    • Figure Japan RNAi for Therapeutic Consumption and Growth Rate (2017-2022)

    • Figure India RNAi for Therapeutic Consumption and Growth Rate (2017-2022)

    • Figure South Korea RNAi for Therapeutic Consumption and Growth Rate (2017-2022)

    • Figure Global RNAi for Therapeutic Consumption Forecast by Country (2022-2028)

    • Figure United States RNAi for Therapeutic Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe RNAi for Therapeutic Consumption Forecast and Growth Rate (2022-2028)

    • Figure China RNAi for Therapeutic Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan RNAi for Therapeutic Consumption Forecast and Growth Rate (2022-2028)

    • Figure India RNAi for Therapeutic Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea RNAi for Therapeutic Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global siRNA Consumption and Growth Rate (2017-2022)

    • Figure Global miRNA Consumption and Growth Rate (2017-2022)

    • Figure Global shRNA Consumption and Growth Rate (2017-2022)

    • Figure Global Cancer Consumption and Growth Rate (2017-2022)

    • Figure Global Cardiovascular Consumption and Growth Rate (2017-2022)

    • Figure Global HBV Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global siRNA Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global miRNA Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global shRNA Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Cardiovascular Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global HBV Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global RNAi for Therapeutic Import by Region (Top 5 Countries) (2017-2028)

    • Table Global RNAi for Therapeutic Export by Region (Top 5 Countries) (2017-2028)

    • Table Dicerna Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Dicerna Pharmaceuticals RNAi for Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

    • Table Dicerna Pharmaceuticals RNAi for Therapeutic Product and Service

    • Table Arrowhead (Foundation Year, Company Profile and etc.)

    • Table Arrowhead RNAi for Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

    • Table Arrowhead RNAi for Therapeutic Product and Service

    • Table Gradalis (Foundation Year, Company Profile and etc.)

    • Table Gradalis RNAi for Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

    • Table Gradalis RNAi for Therapeutic Product and Service

    • Table miRagen Therapeutics (Foundation Year, Company Profile and etc.)

    • Table miRagen Therapeutics RNAi for Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

    • Table miRagen Therapeutics RNAi for Therapeutic Product and Service

    • Table RXi Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table RXi Pharmaceuticals RNAi for Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

    • Table RXi Pharmaceuticals RNAi for Therapeutic Product and Service

    • Table Alnylam Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Alnylam Pharmaceuticals RNAi for Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

    • Table Alnylam Pharmaceuticals RNAi for Therapeutic Product and Service

    • Table Quark Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Quark Pharmaceuticals RNAi for Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

    • Table Quark Pharmaceuticals RNAi for Therapeutic Product and Service

    • Table Sirnaomics (Foundation Year, Company Profile and etc.)

    • Table Sirnaomics RNAi for Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sirnaomics RNAi for Therapeutic Product and Service

    • Table Mirna Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Mirna Therapeutics RNAi for Therapeutic Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mirna Therapeutics RNAi for Therapeutic Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US